Search
Close this search box.

HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Search
Close this search box.

Other HIV-Associated Disease

Management > Other HIV-Associated Disease > References

Sections

Sections

References

  1. Crothers K, Thompson BW, Burkhardt K, Morris A, Flores SC, Diaz PT, et al. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc. 2011;8(3):275-81.
  2. Chinen J, Shearer WT. Molecular virology and immunology of HIV infection. J Allergy Clin Immunol. 2002;110(2):189-98.
  3. Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-Related Lung Disease: Immunity, Infection, and Inflammation. Physiol Rev. 2020;100(2):603-32.
  4. Li JZ, Smith DM, Mellors JW. The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS. 2015;29(12):1429-32.
  5. Charles TP, Shellito JE. Human Immunodeficiency Virus Infection and Host Defense in the Lungs. Semin Respir Crit Care Med. 2016;37(2):147-56.
  6. Brenchley JM, Knox KS, Asher AI, Price DA, Kohli LM, Gostick E, et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol. 2008;1(1):49-58.
  7. Twigg HL, 3rd, Spain BA, Soliman DM, Knox K, Sidner RA, Schnizlein-Bick C, et al. Production of interferon-gamma by lung lymphocytes in HIV-infected individuals. Am J Physiol. 1999;276(2):L256-62.
  8. Costiniuk CT, Jenabian MA. The lungs as anatomical reservoirs of HIV infection. Rev Med Virol. 2014;24(1):35-54.
  9. Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am Rev Respir Dis. 1990;141(5 Pt 1):1356-72.
  10. Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am Rev Respir Dis. 1990;141(6):1582-98.
  11. White DA, Matthay RA. Noninfectious pulmonary complications of infection with the human immunodeficiency virus. Am Rev Respir Dis. 1989;140(6):1763-87.
  12. Crothers K, Huang L. Pulmonary complications of immune reconstitution inflammatory syndromes in HIV-infected patients. Respirology. 2009;14(4):486-94.
  13. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-33.
  14. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388-95.
  15. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26(8):1017-25.
  16. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108-13.
  17. Maitre T, Cottenet J, Beltramo G, Georges M, Blot M, Piroth L, et al. Increasing burden of noninfectious lung disease in persons living with HIV: a 7-year study using the French nationwide hospital administrative database. Eur Respir J. 2018;52(3).
  18. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65.
  19. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765-73.
  20. Kakavas S, Kotsiou OS, Perlikos F, Mermiri M, Mavrovounis G, Gourgoulianis K, et al. Pulmonary function testing in COPD: looking beyond the curtain of FEV1. NPJ Prim Care Respir Med. 2021;31(1):23.
  21. Morris A, George MP, Crothers K, Huang L, Lucht L, Kessinger C, et al. HIV and chronic obstructive pulmonary disease: is it worse and why? Proc Am Thorac Soc. 2011;8(3):320-5.
  22. Lalloo UG, Pillay S, Mngqibisa R, Abdool-Gaffar S, Ambaram A. HIV and COPD: a conspiracy of risk factors. Respirology. 2016;21(7):1166-72.
  23. Bigna JJ, Kenne AM, Asangbeh SL, Sibetcheu AT. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob Health. 2018;6(2):e193-e202.
  24. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130(5):1326-33.
  25. Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, et al. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. Lancet Respir Med. 2016;4(12):980-9.
  26. Finney LJ, Feary JR, Leonardi-Bee J, Gordon SB, Mortimer K. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. Int J Tuberc Lung Dis. 2013;17(5):583-9.
  27. North CM, Allen JG, Okello S, Sentongo R, Kakuhikire B, Ryan ET, et al. HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study. Lung. 2018;196(1):49-57.
  28. Allwood BW, Gillespie R, Bateman M, Olckers H, Taborda-Barata L, Calligaro GL, et al. Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey. S Afr Med J. 2018;108(2):138-43.
  29. Zhang J, Xu Q, Sun W, Zhou X, Fu D, Mao L. New Insights into the Role of NLRP3 Inflammasome in Pathogenesis and Treatment of Chronic Obstructive Pulmonary Disease. J Inflamm Res. 2021;14:4155-68.
  30. Lambert AA, Kirk GD, Astemborski J, Mehta SH, Wise RA, Drummond MB. HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. J Acquir Immune Defic Syndr. 2015;69(1):68-74.
  31. Pocket Guide to COPD Diagnosis, Management, and Prevention. A Guide for Health Care Professionals. Global Initiative for Chronic Obstructive Lung Disease. 2020;2020 Edition.
  32. Fitzpatrick ME, Kunisaki KM, Morris A. Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy. AIDS. 2018;32(3):277-92.
  33. Shirley DK, Kaner RJ, Glesby MJ. Screening for Chronic Obstructive Pulmonary Disease (COPD) in an Urban HIV Clinic: A Pilot Study. AIDS Patient Care STDS. 2015;29(5):232-9.
  34. Lambert AA, Drummond MB, Kisalu A, Moxley J, Keruly J, Moore RD, et al. Implementation of a COPD Screening Questionnaire in an Outpatient HIV Clinic. COPD. 2016;13(6):767-72.
  35. Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, et al. Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. Chest. 2015;148(1):159-68.
  36. The Australian Immunisation Handbook. 2021.
  37. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
  38. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med. 2011;183(5):675-8.
  39. Oursler KK, Goulet JL, Leaf DA, Akingicil A, Katzel LI, Justice A, et al. Association of comorbidity with physical disability in older HIV-infected adults. AIDS Patient Care STDS. 2006;20(11):782-91.
  40. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015;36(4):575-91.
  41. Judson MA MA, Baughman RP. . Sarcoidosis. Philadelphia: Elsevier; 2016.
  42. Lowery WS, Whitlock WL, Dietrich RA, Fine JM. Sarcoidosis complicated by HIV infection: three case reports and a review of the literature. Am Rev Respir Dis. 1990;142(4):887-9.
  43. Miranda EJ, Leite OH, Duarte MI. Immune reconstitution inflammatory syndrome associated with pulmonary sarcoidosis in an HIV-infected patient: an immunohistochemical study. Braz J Infect Dis. 2011;15(6):601-6.
  44. Foulon G, Wislez M, Naccache JM, Blanc FX, Rabbat A, Israel-Biet D, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38(3):418-25.
  45. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE, Jr. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003;124(3):929-35.
  46. Sheikh S, Madiraju K, Steiner P, Rao M. Bronchiectasis in pediatric AIDS. Chest. 1997;112(5):1202-7.
  47. Almeida FA, Jr., Sager JS, Eiger G. Coexistent sarcoidosis and HIV infection: an immunological paradox? J Infect. 2006;52(3):195-201.
  48. Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. Chest. 2002;122(6):2150-64.
  49. Doffman SR, Miller RF. Interstitial lung disease in HIV. Clin Chest Med. 2013;34(2):293-306.
  50. Staitieh B, Guidot DM. Noninfectious pulmonary complications of human immunodeficiency virus infection. Am J Med Sci. 2014;348(6):502-11.
  51. Holmes AH, Trotman-Dickenson B, Edwards A, Peto T, Luzzi GA. Bronchiectasis in HIV disease. Q J Med. 1992;85(307-308):875-82.
  52. Attia EF, Miller RF, Ferrand RA. Bronchiectasis and other chronic lung diseases in adolescents living with HIV. Curr Opin Infect Dis. 2017;30(1):21-30.
  53. King TE, Jr., Lee JS. Cryptogenic Organizing Pneumonia. N Engl J Med. 2022;386(11):1058-69.
  54. Morris AM, Nishimura S, Huang L. Subacute hypersensitivity pneumonitis in an HIV infected patient receiving antiretroviral therapy. Thorax. 2000;55(7):625-7.
  55. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108-13.
  56. Isasti G, Moreno T, PerezI, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29:231-4.
  57. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survivl and prognostic factors in the modern therapeutic era. AIDS. 2010;24: 67-75.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top